Immunome Says FDA Accepted NDA for Desmoid Tumors Drug
() -- Immunome (IMNM) said Wednesday that the US Food and Drug Administration has accepted its new drug application for varegacestat, intended to treat adults with desmoid tumors. The agency assigned a Prescription Drug User Fee Act target action date of April 28, 2027, the company said. The company said its applicatio